Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Optimal response to dimethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile
Silvia Medina, Noelia Villarrubia, Susana Sainz de la Maza, et al.
Multiple Sclerosis Journal (2017) Vol. 24, Iss. 10, pp. 1317-1327
Closed Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

The immunology of multiple sclerosis
Kathrine E. Attfield, Lise T. Jensen, Max Kaufmann, et al.
Nature reviews. Immunology (2022) Vol. 22, Iss. 12, pp. 734-750
Closed Access | Times Cited: 220
Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis
Elizabeth Mills, Magdalena A. Ogrodnik, Andrew Plave, et al.
Frontiers in Neurology (2018) Vol. 9
Open Access | Times Cited: 195
T Helper Cells: The Modulators of Inflammation in Multiple Sclerosis
Martina Kunkl, Simone Frascolla, Carola Amormino, et al.
Cells (2020) Vol. 9, Iss. 2, pp. 482-482
Open Access | Times Cited: 188
Immunological Aspects of Approved MS Therapeutics
Paulus Rommer, Ron Milo, May Han, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 137
Dimethyl fumarate treatment in multiple sclerosis: Recent advances in clinical and immunological studies
Gwendoline Montes Diaz, Raymond Hupperts, Judith Fraussen, et al.
Autoimmunity Reviews (2018) Vol. 17, Iss. 12, pp. 1240-1250
Closed Access | Times Cited: 93
The role of CD56bright NK cells in neurodegenerative disorders
Carla Rodriguez-Mogeda, Chaja M. J. van Ansenwoude, Lennart van der Molen, et al.
Journal of Neuroinflammation (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 13
The NRF2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis
Anna Hammer, Anne Waschbisch, Kristina Kuhbandner, et al.
Annals of Clinical and Translational Neurology (2018) Vol. 5, Iss. 6, pp. 668-676
Open Access | Times Cited: 81
Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis
Sudhir K. Yadav, Devika Soin, Kouichi Ito, et al.
Journal of Molecular Medicine (2019) Vol. 97, Iss. 4, pp. 463-472
Closed Access | Times Cited: 75
Dimethyl fumarate induces a persistent change in the composition of the innate and adaptive immune system in multiple sclerosis patients
Gwendoline Montes Diaz, Judith Fraussen, B. Van Wijmeersch, et al.
Scientific Reports (2018) Vol. 8, Iss. 1
Open Access | Times Cited: 70
Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS
José Ignacio Fernández-Velasco, Jens Kühle, Enric Monreal, et al.
Neurology Neuroimmunology & Neuroinflammation (2021) Vol. 8, Iss. 2
Open Access | Times Cited: 48
Astrocytes and Inflammatory T Helper Cells: A Dangerous Liaison in Multiple Sclerosis
Martina Kunkl, Carola Amormino, Valentina Tedeschi, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 25
Dimethyl fumarate treatment induces lipid metabolism alterations that are linked to immunological changes
Pavan Bhargava, Kathryn C. Fitzgerald, Swarajya Lakshmi Vattem Venkata, et al.
Annals of Clinical and Translational Neurology (2018) Vol. 6, Iss. 1, pp. 33-45
Open Access | Times Cited: 45
CD56bright Natural Killer Cells: A Possible Biomarker of Different Treatments in Multiple Sclerosis
Alice Laroni, Antonio Uccelli
Journal of Clinical Medicine (2020) Vol. 9, Iss. 5, pp. 1450-1450
Open Access | Times Cited: 35
Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity
Erin E. Longbrake, Yang Mao‐Draayer, Mark Cascione, et al.
Multiple Sclerosis Journal (2020) Vol. 27, Iss. 6, pp. 883-894
Open Access | Times Cited: 35
Encephalitogenic and Regulatory CD8 T Cells in Multiple Sclerosis and Its Animal Models
Taryn E. Mockus, Ashley Munie, Jeffrey R. Atkinson, et al.
The Journal of Immunology (2020) Vol. 206, Iss. 1, pp. 3-10
Open Access | Times Cited: 33
High-dimensional immune profiling identifies a biomarker to monitor dimethyl fumarate response in multiple sclerosis
Martin Diebold, Edoardo Galli, Andreas Köpf, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 31
Open Access | Times Cited: 17
Factors associated with dimethyl fumarate-induced lymphopenia
Susana Sainz de la Maza, Silvia Medina, Noelia Villarrubia, et al.
Journal of the Neurological Sciences (2019) Vol. 398, pp. 4-8
Closed Access | Times Cited: 29
Identification of the Immunological Changes Appearing in the CSF During the Early Immunosenescence Process Occurring in Multiple Sclerosis
Carmen Picón, Amalia Tejeda Velarde, José Ignacio Fernández-Velasco, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 22
<p>Drugs for Multiple Sclerosis Activate Natural Killer Cells: Do They Protect Against COVID-19 Infection?</p>
Mena Al‐Ani, Noha Mousaad Elemam, Jennifer E. Hundt, et al.
Infection and Drug Resistance (2020) Vol. Volume 13, pp. 3243-3254
Open Access | Times Cited: 22
A randomized, subject and rater-blinded, placebo-controlled trial of dimethyl fumarate for obstructive sleep apnea
Tiffany J. Braley, Amanda K. Huber, Benjamin M. Segal, et al.
SLEEP (2018) Vol. 41, Iss. 8
Open Access | Times Cited: 22
Increased NK Cell Count in Multiple Sclerosis Patients Treated With Dimethyl Fumarate: A 2-Year Longitudinal Study
Damiano Marastoni, Alessandro Buriani, Anna Isabella Pisani, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 21
Epstein-Barr Virus and multiple sclerosis in a Spanish cohort: A two-years longitudinal study
María Inmaculada Domínguez‐Mozo, Lorena López-Lozano, Silvia Pérez‐Pérez, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 12
The ratio of circulating CD56dim NK cells to follicular T helper cells as a promising predictor for disease activity of relapsing-remitting multiple sclerosis
Jiaqi Ding, Yan Xu, Cong Zhao, et al.
Heliyon (2024) Vol. 10, Iss. 10, pp. e31533-e31533
Open Access | Times Cited: 2
Herpesvirus Antibodies, Vitamin D and Short-Chain Fatty Acids: Their Correlation with Cell Subsets in Multiple Sclerosis Patients and Healthy Controls
María Inmaculada Domínguez‐Mozo, Silvia Pérez‐Pérez, Noelia Villarrubia, et al.
Cells (2021) Vol. 10, Iss. 1, pp. 119-119
Open Access | Times Cited: 15
Dimethyl Fumarate as the Peripheral Blood Inflammatory Mediators Inhibitor in Prevention of Streptozotocin-Induced Neuroinflammation in Aged Rats
Danuta Wrona, Irena Majkutewicz, Grzegorz Świątek, et al.
Journal of Inflammation Research (2022) Vol. Volume 15, pp. 33-52
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top